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Abstract
Objectives To analyse false positives (FPs) in breast cancer
screening with tomosynthesis (BT) vs. mammography (DM).
Methods The Malmö Breast Tomosynthesis Screening Trial
(MBTST) is a prospective population-based study comparing
one-view BT to DM in screening. This study is based on the
first half of the MBTST population (n=7,500). Differences in
FP recall rate, findings leading to recall, work-up and biopsy
rate between cases recalled on BT alone, DM alone and BT+
DM were analysed.
Results The FP recall rate was 1.7 % for BT alone (n=131),
0.9 % for DM alone (n=69) and 1.1 % for BT+DM (n=81).
The FP recall rate for BT alone was halved after the initial
phase of the trial, stabilising at 1.5 %. BT doubled the recall of
stellate distortions compared to DM (n=64 vs. n=33). There
were fewer fibroadenomas and cysts, and the biopsy rate was
slightly lower for FP recalled on BT alone compared to DM
alone (15.3 % vs. 27.6 %: p=0.037 and 33.8 % vs. 36.2 %;
p=0.641, respectively).
Conclusions FPs increased with BT screening mainly due to
the recall of stellate distortions. The FP recall rate was still
well within the European guidelines and showed evidence of a
learning curve. Characterisation of rounded lesions was im-
proved with BT.
Key Points
• Tomosynthesis screening gave a higher false-positive recall
rate than mammography
• There was a decline in the false-positive recall rate for
tomosynthesis
• The recall due to stellate distortions simulating malignancy
was doubled with tomosynthesis
• Tomosynthesis found more radial and postoperative scar
tissue than mammography
• Tomosynthesis is better at characterising rounded lesions
Keywords Digital mammography . Breast tomosynthesis .
Screening . Diagnostic imaging . Breast cancer
Abbreviations





MBTST Malmö Breast Tomosynthesis Screening Trial
MLO Mediolateral oblique
NOS Not otherwise specified
Introduction
Digital mammography (DM) is the standard modality in breast
cancer screening today, but the sensitivity has been shown to
be suboptimal especially in women with dense breasts [1–3].
In recent years, the use of breast tomosynthesis (BT) in screen-
ing has been investigated in several large prospective
population-based trials, showing a substantial increase in the
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cancer detection rate, that is by 30–40 %, when used in addi-
tion to DM [4–7] or as a stand-alone modality [8] and is,
therefore, a candidate for becoming the next generation breast
cancer screening modality. However, data from two of these
prospective screening trials show an increase in the number of
false positives (FPs) when using BT in screening [4, 6, 8] and
might, therefore, be an adverse effect that needs to be analysed
before a largescale implementation of the technique.
Women having an FP result when participating in breast
cancer screening can experience both short- and long-term
psychological distress [9, 10]. As a consequence, these wom-
en may be less likely to participate in subsequent screening
rounds [9]. A high participation rate is an important screening
performance measure in community-based screening
programmes, since low participation rates are associated with
low cost-effectiveness [11]. Furthermore, it has been shown
that women with an FP screening mammogram have an in-
creased risk of breast cancer [9, 12] and it is, therefore, impor-
tant that these women are not lost to the screening programme.
The estimated cumulative risk of an FP screening result in
women aged 50–69 years undergoing ten biennial screening
tests in Europe varies from 8% to 21% [13]. There are several
factors influencing the risk of an FP result, such as a family
history of breast cancer, oestrogen use, breast density and time
between screenings [14, 15].
BT is a tomographic technique where the X-ray tubemoves
at an angle over the breast acquiring multiple low-dose pro-
jections that are reconstructed into a tomosynthesis image vol-
ume, in which each slice typically represents a 1-mm thin
cross-section of the breast [16]. This approach reduces the
detrimental effect of overlapping breast tissue on diagnostic
performance in DM [2, 17], resulting in higher sensitivity [18]
and improved lesion characterisation [19, 20], especially of
spiculated tumours [21, 22]. As a consequence, BT will also
reveal benign lesions that are concealed in DM and sometimes
enhance normal parenchymal components, with the possibil-
ity of increasing the FP rate.
Several large retrospective-screening studies in the USA
have shown the importance of adding two-view BT to two-
view DM in a so-called combination mode in order to lower
the recall rate. In these studies, the recall rate has been reported
to vary between 8.7 % and 16.2 % for DM compared to 5.4 %
and 13.6 % for the combination mode [23–29]. In Europe,
where the recall rates are typically lower (below 5 %) [30],
interim results from two large prospective population-based
screening trials: the Oslo Tomosynthesis Screening Trial and
the Malmö Breast Tomosynthesis Screening Trial (MBTST),
have shown a statistically significant increase in the recall rate
with independent double-reading of DM compared to the
combination mode (2.9 % vs. 3.7 %) [6] or compared to
one-view BT as a stand-alone modality (2.6 % vs. 3.8 %)
[8]. The substantial increase in cancer detection rate contrib-
uted to increasing the recall rate, but there was also a slight
increase in the FP recall rate [6, 8]. Yet, another large prospec-
tive population-based screening trial, the Screening with
Tomosynthesis OR Mammography (STORM) trial, designed
to study the effect of sequential reading of two-view DM and
the combination mode, gave an overall FP recall rate of 5.5 %,
but the FP recall rate for the combination mode was lower
compared to DM (3.5 % vs. 4.4 %). Nevertheless, the combi-
nation mode contributed to an addition of 73 FP cases (FP
recall rate 1.0 %) that were negative on DM alone [7].
The aim of the current study was to characterise FP cases in
breast cancer screening with one-view BT vs. DM with data
from the MBTST, in terms of FP recall rate after arbitration,
the findings leading to recall, the results of the work-up and
biopsy rates. By characterising these cases we might improve
our understanding of the causes leading to a FP result and the
consequences for clinical practice in order to reduce a poten-
tially negative effect of BT in breast cancer screening.
Methods and materials
The Malmö Breast Tomosynthesis Screening Trial
The MBTST is a prospective single-institution one-arm
population-based study designed to compare the efficacy of
one-view BT (mediolateral oblique view (MLO)) as a stand-
alone breast cancer screening modality with two-view DM
(MLO+craniocaudal view (CC)) in women aged 40–74 years
eligible for the screening programme in the City of Malmö
(www.clincaltrials.gov; NCT01091545). The study was
approved by the Regional Ethical Review Board at Lund
University (Dnr 2009/770) and the local Radiation Safety
Board at Skåne University Hospital in Malmö. The MBTST
is described in more detail elsewhere [8]. In short,
participating women underwent a two-view DM as well as a
one-view BT examination (Mammomat Inspiration, Siemens
AG, Erlangen, Germany). The DM and BT images were sub-
jected to independent blinded double reading and scoring in
two independent reading arms, where findings were rated on a
5-point scale: (1) normal, (2) benign findings, (3) non-specific
finding with low probability of malignancy, (4) findings sus-
picious of malignancy, and (5) findings highly suspicious of
malignancy.
The two reading arms comprised three reading steps each.
Each step was scored before proceeding to the following step.
In the BT reading arm, BTalone was scored first (step 1); then
with the addition of the DMCC view (step 2); and finally with
the addition of prior DM if available (step 3). In the DM
reading arm, DM alone was scored first (step 1) followed by
the addition of prior DM (step 2). Breast density was classified
according to BI-RADS (4th Edition) in the DM reading arm at
reading step 3 [31]. If in either or both of the reading arms a
case was given a score of 3 or higher by one of the two
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readers, it was referred for arbitration. At the arbitration meet-
ing, at least two readers re-evaluated the images and decided
whether to recall the woman for further work-up, irrespective
of the scores in the other reading arm. Thus, women could be
recalled based on findings only on the BT reading arm, the
DM reading arm or both reading arms (here called BT alone,
DM alone and BT+DM recall group). Women reporting
symptoms at the screen examination, e.g. palpable lump,
could be recalled in spite of negative imaging findings. As
reported previously [8] the cancer detection rate for BT was
8.9/1,000 screens and 6.3/1,000 screens DM. The recall rate
after arbitration was 3.8 % for BTand 2.6 % for DM. The PPV
was 24 % for both BT and DM. The MBTST is planned
to include 15,000 women with a complete set of BT and
DM images. This study is based on data from the first
half of the MBTST population (n = 7,500 women) who
participated in the study between January 2010 and
December 2012.
Image acquisition
Two-view DM was immediately followed by one-view BT
(Mammomat Inspiration, Siemens AG, Erlangen, Germany).
BT images were acquired using the same beam quality and
anode/filter combination (W/Rh) as DM. The automatic expo-
sure control was set to yield an average glandular dose (AGD)
of 1.2 mGy per DM image and 1.6 mGy for BT, for a standard
breast of 53 mm consisting of 50 % glandular tissue and 50 %
fatty tissue. Hence, the absorbed dose in a one-view BT was
approximately 70 % of the absorbed dose in a two-view DM.
The BT examination consisted of 25 projection images ac-
quired over an angular range of 45°. These images were re-
constructed into 1-mm slices using a generalised filtered back-
projection reconstruction algorithm [32]. The BTexamination
was performed with reduced compression force of the breast
compared to the previously acquired DM examination, with
the goal of a 50 % reduction [33].
False-positive (FP) cases
An FP case was defined as a recalled woman who was con-
sidered disease-free after work-up and at least a 3-year follow-
up and through record linkage with the South Swedish Cancer
Registry. Parameters collected from the MBTST were FP re-
call rate after arbitration, including FP recall rate over time
and population characteristics (i.e. age and breast density)
and biopsy rates. The FP cases were also analysed retrospec-
tively by an expert panel consisting of three breast radiologists
(mean 17 years’ experience, range 1–42 years) and one med-
ical student to assess the radiographic finding leading to recall
and outcome of the work-up. Radiographic findings leading to
recall were rendered through the primary description carried
out by the radiologists at the arbitration meeting or by the
radiologist performing the initial work-up. If there was no
distinct description of the finding, the expert panel categorised
the finding by consensus. The following categories were used:
stellate distortion, rounded lesion, indistinct density, calcifica-
tions, architectural distortion and symptoms. In the evaluation
of the radiographic findings in the BT+DM recall group, the
appearance on BT was chosen if there was a discrepancy be-
tween the modalities.
Statistical analyses
Descriptive statistics (numbers and percentages) were used to
analyse and present the data. A Chi2 test was used to analyse
differences in the proportions of findings leading to recall
between the DM-alone and BT-alone recall group. Fisher’s
exact test was used to analyse the outcomes of the work-up
and biopsy rate since there were few observations. Although
there were three recall groups, we found the comparison of the
DM-alone and BT-alone recall groups most relevant from an
imaging perspective, since almost one-third of all women
recalled in the BT+DM group were recalled due to the
reporting of symptoms.
Results
FP recall rate after arbitration
Out of 7,500 screened women a total of 352 were recalled for
work-up. Three women were excluded from the analysis, in-
cluding one woman diagnosed with lymphoma and two wom-
en declining the work-up. Sixty-eight women were shown to
have breast cancer and 281 were FPs. FP recall rate after
arbitration for BT alone was 1.7 % (n=131), for DM alone
0.9 % (n=69) and for women recalled on both BT+DM 1.1 %
(n=81) (Fig. 1). The majority of the cases were selected at
reading step 1 (Table 1). The contribution of FP cases with
the addition of prior DM was minor in the BT-alone
and DM-alone recall groups (two cases per group). As
expected, symptomatic women were mainly found in the
BT+DM recall group.
The mean FP recall rate over time (1.5 years) for BT alone
was 1.9 % (range 1.5–3.3), for DM alone 0.9 % (range 0.4–
1.2) and for BT+DM 1.0 % (range 0.6–1.5). The FP recall rate
for BT alone was halved during the first 1.5 yeary of the
MBTST, stabilising on an FP recall rate of about 1.5 %
(Fig. 1).
Characteristics of the FP cases
The characteristics of the FP cases in the different recall
groups are shown in Table 2.
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Age and density
Women recalled on BT+DM were slightly younger and had
denser breasts compared to the women recalled on DM and
BTalone. The women in the BT-alone recall group had slight-
ly fattier breasts, compared to the other recall groups.
Finding leading to recall
Overall, the finding of an area of stellate distortion was the
major cause of an FP in both modalities. There was a higher
proportion of stellate distortions leading to a recall on BT
alone compared to DM alone (n = 53, 40.5 % (95 % CI
32.1–49.4) vs. n = 22, 31.9 % (22.6–42.8); p = 0.234,
χ2(1)=1.418). In total, BT led to a doubling of the recall of
stellate distortions compared to DM (n = 64 vs. n = 33).
Furthermore, there were slightly fewer rounded lesions in
the BT-alone group compared to DM alone (n=32, 24.4 %
(16.9–33.9) vs. n = 18, 26.1 % (16.1–39.3); p = 0.797,
χ2(1) = 0.066). Women presenting with symptoms was the
main reason for an FP in the BT+DM recall group (n=29,
35.8 %).
Outcome of the work-up
The most frequent outcome for all FP cases was tissue that
was considered free of abnormality, i.e. typically normal glan-
dular tissue. This was also true for the majority of the addi-
tional FP cases attributed to screening with BT (n = 74,
56.5 %) (Fig. 2, Case 1).
The work-up of all BT-alone cases resulted in the
finding of more radial scars (n = 5) (Fig. 3, Case 2),
postoperative scar tissue (n = 8) and benign lesions not
otherwise specified (NOS) (n = 5), compared to the DM-
alone group (n = 0, n = 1 and n = 1, respectively). On the
other hand, there were significantly fewer rounded le-
sions (fibroadenomas and cysts) in the BT-alone group
compared to the DM-alone group (n = 20, 15.3 % (95 %
CI 10.9–21.0) vs. n = 19, 27.6 % (18.2–39.3); p = 0.037).
The work-up of women recalled on both BT+DM re-
sulted mostly in the finding of benign cysts (n = 20,
24.7 %).
In most cases, the assessment stellate distortions in
all three recall groups (n = 86) led to the finding of
normal breast tissue (Fig. 4). Stellate distortions recalled
on BT alone contributed to the finding of normal tissue
(n = 43), radial scars (n = 5), postoperative scar tissue
(n = 4) and one cyst (Fig. 4). The work-up of radio-
graphic findings with a rounded appearance recalled on
BT alone resulted in cysts (n = 10), fibroadenomas
(n = 5), normal tissue (n = 8), benign NOS (n = 4), lymph
node (n = 2), atheroma (n = 2) and postoperative scar tis-
sue (n = 1) (Fig. 4).
Biopsy rate
The work-up of FP cases recalled on both BT+DM needed
most biopsies (Fig. 5). The assessment of BT-alone cases had
a slightly lower total biopsy rate compared to the DM-alone
recall group (n=43, 32.8 % (95 % CI 24.9–41.6) vs. n=25,
36.2 % (25.0–48.7); p=0.641). This was due to a lower fine
needle aspiration rate (n=37, 28.2 % (20.7–36.8) vs. n=23,
33.3 % (22.5–45.7); p = 0.517), but the core-needle biopsy
rate was slightly higher in the BT-alone group compared to
DM alone (n=6, 4.6 % (1.7–9.7) vs. n=2, 2.9 % (0.4–10.1);
p=0.717).
Discussion
The result of this study indicates that breast cancer
screening with BT will lead to an increase in the recall
of stellate distortions, of which the majority will show
Fig. 1 False-positive recall rate over time. False-positive recall rate for
breast tomosynthesis (BT) alone, digital mammography (DM) alone and
for cases recalled on both BT+DM during the first half of the Malmö
Breast Tomosynthesis Screening Trial
Table 1 Reading steps. Number of positive scores (rated 3 or higher) in
the recall groups that resulted in a false-positive case in the two
independent reading arms: Reading arm BT: one-view breast
tomosynthesis (BT) alone (step 1); the addition of one-view digital
mammography (DM) craniocaudal view (step 2); comparison with prior
two-view DM, if available (step 3). Reading arm DM: two-view DM
(step 1); and comparison with prior DM (step 2)
BT alone (n) DM alone (n) BT+DM (n)
BT DM
Symptoms 4 3 29 29
Step 1 122 64 45 51
Step 2 3 2 6 1
Step 3 2 n/a 1 n/a
Total 131 69 81 81
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no evidence of abnormality after assessment and follow-
up, but will also result in a higher frequency of radial
scars and postoperative scar tissue. On the other hand,
BT was found to be better at characterising rounded
Table 2 False positives.
Characteristics of the false-
positive cases in the different
recall groups: breast
tomosynthesis (BT) alone, digital
mammography (DM) alone and
women recalled on both BT+DM
BT alone DM alone BT+DM
Mean age, years (range) 53 (40–74) 55 (40–75) 51 (40–72)
Density
Fatty (BI-RADS 1+ 2) 53 (40.5) 26 (37.7) 27 (33.3)
Dense (BI-RADS 3+ 4) 78 (59.5) 43 (62.3) 54 (67)
Total 131 (100) 69 (100) 81 (100)
Finding leading to recall
Stellate distortion 53 (40.5) 22 (31.9) 11 (13.6)
Rounded lesion 32 (24.4) 18 (26.1) 24 (29.6)
Indistinct density 28 (21.4) 20 (29.0) 8 (9.9)
Calcifications 12 (9.9) 5 (7.2) 9 (11.1)
Architectural distortion 2 (1.7) 1 (1.4) 0 (0)
Symptoms 4 (2.5) 3 (4.3) 29 (35.8)
Total 131 (100) 69 (100) 81 (100)
Outcome of the work-up
Normal breast tissue 74 (56.5) 39 (56.5) 21 (25.9)
Benign cyst 15 (11.5) 13 (18.8) 20 (24.7)
Benign calcifications 12 (9.2) 7 (10.1) 10 (12.3)
Postoperative scar tissue 8 (6.1) 1 (1.4) 1 (1.2)
Other a 6 (6.9) 2 (2.9) 8 (9.9)
Fibroadenoma 5 (3.8) 6 (8.7) 10 (12.3)
Benign lesion (NOS)b 5 (3.8) 1 (1.4) 3 (3.7)
Radial scar 5 (3.8) 0 (0) 4 (4.9)
Symptomatic women with negative work-up 1 (0.8) 0 (0) 4 (4.9)
Total 131 (100) 69 (100) 81 (100)
Data are n (%) or range when stated
a Various benign findings (≤2 findings per lesion type), e.g., lymph node, atheroma, lipoma, oil cyst, hamartoma,
papilloma
b Benign lesion not otherwise specified (NOS) was the finding of a small lesion with benign features that was
stable on follow-up, but where needle-biopsies could not be performed
a b c
Fig. 2 False positive case recalled on breast tomosynthesis alone. Case
1.A 60-year-old asymptomatic womanwas considered to have a negative
screening mammogram at double-reading (a), but was recalled due to the
finding of a stellate distortion on breast tomosynthesis (mediolateral
oblique view) (b). However, at work-up there was no discernible lesion
at ultrasonography or magnetic resonance imaging. The finding was sta-
ble at 1-year follow-up (c) and was considered to be ordinary
fibroglanduar tissue
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lesions, reducing the assessment of benign cysts and
fibroadenomas compared to cases recalled on DM alone.
The drop in the FP recall rate for BT alone during the first
1.5 years of the trial implies that the specificity can be im-
proved with increased experience. The FP recall rate stabilised
at 1.5 %. Assuming that this is the likely level in a routine
screening in our group the difference against DM would be
small. Furthermore, if the readers had had access to prior BT
examinations, a further reduction in the FP recall rate might
have been achieved [34, 35]. Also, since BT is a more sensi-
tive method, the use of BT in the MBTST population should
be regarded as a prevalence screening round, with a higher
recall and cancer detection rate compared to incidence screen-
ing. Had the same population been screened with BT for a
second round, the recall rate and cancer detection rate would
most likely be lower. Nevertheless, the observed FP recall rate
for BT in this study was low and in accordance with the
European Guidelines for Quality Assurance in Breast Cancer
Screening and Diagnosis [36], and is probably outweighed by
the benefits of a significant increased cancer detection rate [8].
Hence, using only one-view BT in the MBTST did not seem
to compromise the diagnostic performance since the results
are comparable with the population-based screening trials that
used a combination of two-view BT and two-view DM.
Fig. 3 False positive case
recalled on breast tomosynthesis
alone. Case 2. A 54-year-old
asymptomatic woman with
negative screening
mammography (a) was recalled
based on the finding of a small
area of stellate distortion visible
only on breast tomosynthesis (b).
At work-up, ultrasound (c)
showed a subtle stellate distortion
without a distinguishable nucleus
and fine needle aspiration showed
no evidence of malignancy. It was
considered to most likely
represent a radial scar
Fig. 4 Work-up of false-positive
cases. The result (number) of the
work-up of women recalled due
to a finding of an area of stellate
distortion or with a rounded
radiographic appearance for the
different recall groups: Breast
tomosynthesis (BT) alone, digital
mammography (DM) alone and
women recalled on both BT+DM
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However, it should be borne in mind, that a significant factor
when comparing FP rates between different studies is the cut-
off-level between different radiographic abnormalities.
Furthermore, in addition to a high accuracy a mass screening
modality should be fast, easy to read and reasonably inexpen-
sive. One-view BT has the potential to meet these criteria.
Further follow-up of theMBTSTwill showwhether this holds
true.
The observed increase of radial scars and postoperative scar
tissue is attributed to the fact that BT is especially sensitive to
stellate lesions, including both benign and malignant lesions, as
observed in the additional cancers detected in the MBTST [8],
as well as in the Oslo Tomosynthesis Screening Trial [4, 6]. The
higher sensitivity of BT could also have contributed to the
increased detection of benign lesions NOS – lesions that, due
to their subtlety, were not discernible on ultrasonography, and
hence not accessible to needle biopsy, but stable at follow-up.
Hypothetically, this type of assessment could lead to more dis-
tress for the woman. Longer follow-up of the FP cases recalled
on BT alone might add important knowledge, since it could
answer the question of whether some of these findings actually
represent a very early sign of a developing malignancy [9, 12].
At the breast clinic where the study was performed, there was
no access to BT-guided biopsy, which could also explain the
lower biopsy rate in the BT-alone group. Previous studies have
shown increased performance by using vacuum-assisted biopsy
with the aid of BT compared to prone stereotactic biopsy [37,
38]. Although it has been shown that most women with an FP
DM do not undergo an invasive assessment [13], there is no
doubt that access to this technology will be useful if BT is to be
used in screening, especially to assess subtle lesions not visible
on conventional mammography and ultrasound.
Lourenco et al. [26] showed that the implementation of the
combinationmode in screening gave an overall reduction in the
recall rate, mainly due to fewer recalls of abnormalities present-
ed as focal asymmetries. There were too few observations of
asymmetries in this study to draw any similar conclusions. This
discrepancy could be explained by the choice of nomenclature
in the retrospective assessment of the radiographic findings and
possibly by differences in the study populations.
This study did not show any major differences in age and
breast density in the FP cases recalled on BTalone versus DM
alone. In a previous study performed by this group, the same
data set was analysedwith another statistical approach in order
to obtain a model to predict the total number of FP when
screening with BT [15]. The study showed that the FP fraction
for both screening modalities, BT and DM, increased with
breast density.
A clinical implication of this study is that, regardless of
whether BTwill increase or reduce the FP recall rate in breast
cancer screening (depending on baseline recall rates), there
will most likely be a shift in the type of FP cases that the
radiologist needs to assess. Some of these cases – only visible
on BT – will also be difficult to assess without access to BT-
guided biopsies, magnetic resonance imaging or short-term
follow-up. Before a large-scale implementation of BT in
screening takes place, further analyses of the cost-benefit is
needed. The cost of FP has been estimated to be almost one-
third of the cost of a DM screening programme [39]. This
warrants further studies of what type of examinations and
investigations are needed to assess the FP cases generated
with BT screening.
We have chosen to present the FP recall rate after arbitra-
tion, since it reflects the actual impact on clinical practice.
However, the pre-arbitration FP recall rate could also add
valuable information, since the arbitration meetings for the
separate reading arms were not fully blinded, but this is be-
yond the scope for this study. A limitation of this study is the
lack of prior BT examinations for comparison, as discussed
above. Other limitations related to the design of the MBTST
are discussed in detail elsewhere [8].
In conclusion, in the first half of this population-based
screening trial with one-view BT the number of FPs increased
mainly due to the recall of stellate distortions simulating ma-
lignancy. On the other hand, the characterisation of rounded
lesions was improved with BTcompared to DM, reducing the
need to assess cysts and fibroadenomas. With increased expe-
rience the FP recall rate can be reduced.
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